E. Coli

The ideal transport vehicle for next-gen vaccines?

Most people recoil at the thought of ingesting E. coli. But what if the headline-grabbing bacteria could be used to fight disease? Researchers experimenting with harmless strains of E. coli — yes, the majority of E. coli are safe and important to healthy human digestion — are working toward that goal. They have developed an E. coli-based transport capsule designed to help next-generation vaccines do a more efficient and effective job than today’s immunizations.

Researchers have developed an E. coli-based transport capsule, the downloadable...
Researchers have developed an E. coli-based transport capsule, the downloadable image above, designed to help next-generation vaccines do a more efficient and effective job than today’s immunizations.
Source: University at Buffalo
The core of the transport capsule is harmless E. coli. A synthetic polymer —...
The core of the transport capsule is harmless E. coli. A synthetic polymer — poly (beta amino ester), or PBAE — wraps around the bacteria. The positive-charged polymer, combined with the negative-charged bacteria cell wall, create a hybrid capsule.
Source: University at Buffalo

The research highlights the capsule’s success in fighting pneumococcal disease, an infection that can result in pneumonia, sepsis, ear infections and meningitis.“It’s a bit counterintuitive given what you hear about E. coli, but there are many strains of the bacteria, most of which are perfectly normal in the body, that have great potential to fight disease,” said Blaine A. Pfeifer, PhD, associate professor of chemical and biological engineering in the University at Buffalo School of Engineering and Applied Sciences. Pfeifer is the study’s co-lead author along with his former student Charles H. Jones, PhD, who is leading efforts to commercialize the biotechnology as CEO and founder of Buffalo, New York-based startup Abcombi Biosciences.

The core of the transport capsule the team developed is harmless E. coli. Around the bacteria, the researchers wrapped a synthetic polymer — called poly (beta amino ester) — that resembles a chain link fence. The positive-charged polymer, combined with the negative-charged bacteria cell wall, create a sort of hybrid capsule.

To test the capsule, the researchers then inserted a protein-based vaccine, also being commercialized by Abcombi, designed to fight pneumococcal disease. The results, when tested in mice, were impressive.

The capsule’s hybrid design provided:

  • Both passive and active targeting of specific immune cells called antigen-presenting cells that trigger an immune response.
  • Natural and multicomponent adjuvant properties, which enhance the body’s immune response.
  • Dual intracellular delivery mechanisms to direct a particular immune response.
  • Simultaneous production and delivery of the components (antigens) required for a vaccine.
  • Strong vaccination protection capabilities against pneumococcal disease.

It’s also relatively inexpensive to create and flexible in terms of use. For example, the capsule could be used as a delivery device for therapies that target cancer, viral-based infectious disease and other illnesses.


Source: University at Buffalo

14.07.2016

Read all latest stories

Related articles

Photo

News • Antibacterial cellulose

A wound dressing that kills bacteria

In order to combat bacterial wound infections, Empa researchers have developed cellulose membranes equipped with antimicrobial peptides. Initial results show: The skin-friendly membranes made of…

Photo

Article • Antimicrobial stewardship

A diagnostic marker reduces antibiotics use

Since 2009, as part of diagnostic and antimicrobial stewardship strategies, Hampshire Hospitals National Health Service (NHS) Trust has used serum procalcitonin (PCT) – an innovative and highly…

News • Survey

DNA Electronics tackles the growing threat of antibiotic resistance

DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new point-of-need test for blood infections, highlights the urgent need for fast diagnostics…

Related products

Subscribe to Newsletter